This is an excellent effort to make sense of the Yang

New Post Public Reply Private Reply Replies (1) Message Board
dfwl28
945
This is an excellent effort to make sense of the Yang findings which conflict with the original understanding of LL's MoA.

Hope some of my betters here will discuss and evaluate.


My Thoughts on the Recent Long Hauler's Trial and the Implications

The recent news on the weekly administration of 700mg sub-q Leronlimab to Long Hauler patients that resulted in increasing numbers of CCR5 was an unexpected and significant finding. My understanding and interpretation, I make here.

Essentially, the researchers that conducted the study seem to feel that patients who have long haulers have it because their immune systems had been weakened by the Covid 19 disease and that the weakening brought their CCR5 levels down. I would agree that fighting Covid 19, puts your immune system through hell and that it "ages" many of your Immune fighting T-Cells & B-Cells and certainly may down regulate the number of CCR5 receptors found on the cell's surface. The doctors found that in the Leronlimab treated arm, those patients were found to have and increased number of CCR5 while those who were in the Placebo treated arm, did not have an increase in their CCR5 cell surface count. The researches concluded that Leronlimab may "normalize" CCR5 levels if they were abnormally low. But they did not give a means by which that happens.

I am thinking that this mechanism is along the lines of a bodily reaction; sort of like a reflexive response to the drop in required communication & signaling which was resulted with every new administration of weekly Leronlimab. In general, based on the stimulus level or the disease level, there ought to be a certain level of communication and messaging being performed by the CCR5 receptors. As the stimulus of disease increases, the body would upregulate CCR5 to increase the level of signaling, communication messaging and when the stimulus of disease decreases, the body would tone down CCR5 quantities which perform that messaging. However, in Long Haulers, although there was a significant stimulus of disease, there wasn't sufficient messaging being performed, and researchers believe that CCR5 levels were down because the Immune System was fatigued from overwork fighting Covid 19 and now Long Haulers, but when Leronlimab was added, the CCR5 messaging increased and the patient's immune fighting capacity was ramped up.

Here is how I see it: When the patient's received their Leronlimab injection, Leronlimab bound to CCR5 with a strong affinity. This binding disabled only a portion of the CCR5 functionality, not all of it's functionality. Specifically, Leronlimab blocks CCR5's capacity to message the Innate Immune System which is the "Acute Immune Response to invasion or to infection". This Innate Immune Response entails messaging to the Macrophages (which increase in bacterial infection), to the Eosinophils (which increase in number in allergic response), to Basophils, Dendrites and Natural Killer Cells all of which are extremely inflammatory. However, the binding of Leronlimab to CCR5 does not impact CCR5's capacity to message the cells which comprise the Adaptive Immune Response, (which is the response produced by the body for chronic diseases, and therefore, the response which happens over time). The white blood cells that entail the Adaptive Immune Response are the Lymphocytes (which increase in chronic infection or viral attacks), monocytes (increasing in chronic inflammatory disease, parasitic infections), the T-Cells and the B-Cells (which are responsible for the manufacturing of antibodies and the memory of these antibodies).

So my theory is that as these Long Hauler patients received the series of Leronlimab injections, the Leronlimab bound to the CCR5 receptors, thereby disabling the patient's Natural Innate Immune Response. The messaging & signaling of the macrophages, eosinophils, basophils, Dendrites and Natural killer cells were all shut down. The body quickly recognized the loss of cellular chemical communication in this respect and therefore produced more CCR5 as a "reflex", almost like a PID controller, (Proportional, Integral, Derivative controller). When the return of the signaling and messaging went back as feedback to the PID Loop Controller, to what the "set point" asked for, given the current disease state and level of stimulus, the controller was satisfied and since Leronlimab was not around to take away CCR5 communication, the controller went into homeostasis and maintained current setpoint / output.

The next week comes along and the patient received the 2nd Leronlimab injection. Again, Leronlimab has such strong affinity to CCR5, with which it bound 100% to CCR5 and again, the signaling and messaging in the Innate Immune Response became zilch. The body's PID loop controller picked that up as negative feedback and produced a derivative signal for more CCR5 receptors in response. The Innate Immune Response was ramped back up to what was expected and since the CCR5 molecules were produced after the Leronlimab injection, those CCR5 receptors were not bound to Leronlimab, and signaling and messaging communication was re-established.

The 3rd injection of Leronlimab again boosted CCR5 levels. It was given and again all the CCR5 in the body became 100% bound with Leronlimab and again the body became deficient in the Innate Immune Response. The body's PID loop controller ramped up the production of CCR5 until Innate Immune communication came up to par. This cycle happened over and over until the 8th injection which resulted in an overall increased numbers of CCR5.

All of this may have happened because of the stimulus or the call for the Innate Immune Response to ramp up due to the invader which was likely the spike protein from Covid or the spike protein from the vaccination. The invader was the stimulus which caused the Immune Response to call for the Macrophages, Eosinophils, Basophils, Dendrites and Natural Killer Cells to rise, increase in number and attack the invader, all of which are extremely inflammatory. However, with every dosage of Leronlimab, this communication, signaling and messaging capacity of CCR5 was toned down, thereby reducing inflammation, but the Adaptive messaging continued.

However, with the ever increasing number of CCR5, the capacity of CCR5 to message and communicate with the Adaptive Immune Cells including the Lymphocytes, monocytes, the T-Cells and the B-Cells went up with every injection of Leronlimab. Not because Leronlimab augments this communication in any way, but rather because the body produced more CCR5 in response to the binding effects Leronlimab had on CCR5, (the loss of communicative capacity in the Innate system). Since Leronlimab did not impair the messaging and signaling upon the cells of the Adaptive Immune Response, the long term cure for the disease could be made faster and better with more messaging and communication with the increased numbers of CCR5.

Given that Long Haulers is a disease with many varied symptoms (heterogenous), the body is dealing with an attack by a pathogen it hasn't ever dealt with. In addition, these patients have lived with the disease for months. Therefore the disease is chronic. The patient also has not yet developed a means to cure him/herself of the disease, (Adaptive Response is poor). This means the patient is immuno-compromised, at least for this disease, he is. He / She has a disease which they are unable to cure themselves of and that makes them immunocompromised. Leronliimab comes on board and effectively gives them the necessary tools to overcome their problem, an increase in the communication and messaging of the Adaptive Immune System. Therefore, we can claim that Leronlimab ramps up the immune system if it is abnormally suppressed.


What implications could that point to? Immunosuppression is common in many disorders, especially cancer and diabetes. Especially those who require chemotherapy. Chemotherapy acts like a poison. What do you think that does to someone's immune system? Their entire immune system, both Innate and Adaptive are both probably dead from the chemo itself. All white blood cell lines fatigued to the point of exhaustion trying to fight off the chemo. How low do you think the CCR5 count is in chemo patients? Probably zero. Many elderly too are immunosuppressed. Somehow, they are unable to mount the appropriate response when they become infected. Could they have low CCR5 levels as they age? Diabetics who have difficulty with glucose control tend to be immunosuppressed. Could higher sugar levels have an effect on CCR5 surface expression? And what about those who require long stents of and large doses of prednisone and cortisone. Their immune systems are suppressed. Could cortisone itself interact with CCR5 and disable it? Many auto-immune patients see rheumatologists are prescribed cortisone and other anti-inflammatory medications, many of which are called DMARDs which are Disease Modifying Anti-Rheumatic Drugs. These medications suppress select portions of the immune system so the patient no longer suffers from diseases which attack the person him/herself, which are auto-immune disorders.

By this extrapolation, we can see that it is feasible that Leronlimab be added in conjunction with any/all of these disorders to boost patient's immune system capacity so they do not develop life altering diseases such as pneumonia, influenza, cellulitis, hard to treat infections of the body and brain, diseases of the organs, etc, etc... while they are immunocompromised or immunosuppressed either alone or in combination therapy with their treatments.

I tend to think that if Leronlimab is given to a patient, and if the patient is healthy, say there is no underlying disease, then, yes, Leronlimab will bind to 100% of CCR5, but since there is no underlying disease, the body does not subsequently call for an activation of the Innate Immune Response and therefore there is no call for an increase in number of CCR5. If that patient, while on Leronlimab therapy, develops a disease, then the body will call for the Innate Immune Response, but will find that none was issued, because it was blocked by Leronlimab, then the body will immediately call for more CCR5 to be manufactured and expressed on the cells surface. When the body has reached homeostasis, as determined by the PID Loop Controller, then the number of CCR5 will normalize in accordance with the disease level of that stimulus.

Now to answer the question about what is the PID Controller in the body, that is like answering the question as to why do all the trees bloom on the same day after months of cold hibernation. Or how do all the bugs on a bush, flicker all at once, simultaneously in unison, as if there were some invisible communication between them all. Something senses the communication and something upregulates the quantity of CCR5 on the cell surface, but what that something is, it does a good job when the system is healthy, but when the person is old or cancer ridden requiring chemo, diabetic or drugged with DMARDS, then it doesn't work as well as it should.

Adding to what we already have known about this drug, Leronlimab has massive potential. I think we are only on the surface of learning everything it's capable of.

CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

America's Group Adds Swansea to Its UK Auction Map

Updated Category News Views 19

A Welsh Lane Joins a Larger Road Port Talbot just became a small but telling dot on America's Group's international map. The company has acquired Swansea Motor Vehicle Auction Limited, a long-standing South Wales wholesale and remarketing operation, and plans to run it under the G3 brand. This is not the sort of deal that makes markets levitate. It is the sort that tells...

Continue Reading
Mantle's Japan Listing Puts $MNT Through a Real Test

Updated Category News Views 88

Japan's crypto gatekeepers just handed Mantle a key, not a crown. The November 18 listing of $MNT on GMO Coin is a meaningful operational win because getting onto a Japanese centralized exchange is not the usual loose-change exercise seen in friendlier jurisdictions. Mantle cleared a review process involving GMO Coin and the Japan Virtual and Crypto Assets Exchange...

Continue Reading
Xailient Tops NIST for Real-World AI Face Recognition

Updated Category News Views 87

In a world where bigger ain't always better, Xailient's latest triumph at NIST's face recognition test has set them apart. On November 17, 2026, the U.S. National Institute of Standards and Technology (NIST) crowned Xailient as the leader in face recognition accuracy for on-device AI, leaving 105 others in the dust. This ain't your run-of-the-mill achievement—it shows...

Continue Reading
AES Clears FERC, Nearing Its December 2 Takeover Close

Updated Category News Views 119

One more regulatory gate just swung open for AES, and this deal is finally staring at the finish line instead of wandering through the usual approval swamp. The Federal Energy Regulatory Commission has issued its final order approving AES's acquisition by a consortium led by Global Infrastructure Partners, part of BlackRock, and EQT Infrastructure VI. The last major...

Continue Reading
Triple Crossing Tests a Tough Inland Marine Market

Updated Category News Views 150

Inland marine is where tidy insurance appetites go to get bent out of shape. A contractor’s rented machine, cargo moving between points, a half-finished building, or equipment that is neither parked forever nor easy to classify can turn a standard quote into a week of broker phone calls. Triple Crossing Specialty is stepping directly into that mess, launching a new...

Continue Reading
ELEGOO's Formnext Push Tests a Broader 3D Ambition

Updated Category News Views 123

Frankfurt’s show floor is where product promises meet some very unforgiving eyeballs. ELEGOO arrived at Formnext 2026 with more than a refreshed machine or two: it is laying out a wider bet across resin printing, FDM printing, and 3D scanning. That matters because the company is no longer presenting itself as merely a supplier of affordable creator hardware. It wants to...

Continue Reading
Animal Parasite Market Growth Has a Resistance Catch

Updated Category News Views 156

Flea collars and cattle worms do not sound glamorous, yet this is exactly where durable animal-health revenue gets built. Wissen Research puts the global animal parasiticides market at $13.6 billion in 2026 and projects $18.6 billion by 2031, a 6.5% compound annual growth rate. That is respectable, not moonshot stuff, and frankly that is part of the appeal. Pet owners...

Continue Reading
Stitch AI Targets Banking’s Hardest Automation Gap

Updated Category News Views 15

The flashy chatbot stuff is cheap; banking permission to act is not. That is why Stitch AI’s launch deserves more attention than another vendor slapping “agentic” on a slide deck and calling it transformation. Banks do not need a machine to summarize a policy document while everyone applauds the demo. They need technology that can touch real workflows without...

Continue Reading
Dolby's Strong Quarter Meets a Flat 2027 Reality Check

Updated Category News Views 81

A licensing machine just coughed up a very good quarter, then told investors not to expect the engine to accelerate next year. That is the whole Dolby story in one uncomfortable breath. NYSE:DLB finished fiscal 2026 with fourth-quarter revenue of $374 million, up from $307 million a year earlier, while GAAP diluted earnings climbed to $0.86 from $0.51. Those are not...

Continue Reading
Thoughts Unleashed Arrives With a Personal American Voice

Updated Category News Views 114

A lifetime of observation finally gets its own page Forty is an unusual age to begin writing poetry, which is exactly why Joyce Ann Grooms McGeehan's debut has a little more texture than the usual polished promise of inspiration. Thoughts Unleashed by an Independent, American Woman comes from someone who spent decades teaching French, English, and ESL, then retired to a...

Continue Reading

Top 5 Most Recently Viewed Articles

Exciting Changes in Leadership Position at ibex Limited

Updated Category News Views 289

Board of Directors' Transformation at ibex Limited ibex Limited, a prominent player in global business process outsourcing, has recently made significant changes to its Board of Directors. The company announced that Gerard Kleisterlee will retire from his position after the upcoming Annual General Meeting (AGM). A Fond Farewell to Gerard Kleisterlee Gerard has been an...

Continue Reading
Umicore's Shareholding Update: Impact and Insights

Updated Category News Views 148

Investor Transparency Notification from Silchester International Investors LLP Transparency notification by Silchester International Investors LLP Umicore has recently received a significant transparency notification regarding shareholding changes from Silchester International Investors LLP. This notification falls under the legal obligations concerning major holdings as...

Continue Reading
Exploring the Future of Retail at Digital Retail Africa 2025

Updated Category News Views 212

Event Overview of Digital Retail Africa 2025 The retail landscape is experiencing significant change, and Digital Retail Africa 2025 aims to prepare businesses for the rapidly evolving challenges and opportunities that lie ahead. This influential event, scheduled for January 30, 2025, at a premier venue, will gather top industry professionals, innovators, and...

Continue Reading
Understanding the Impact of Wegovy's Medicare Negotiation

Updated Category News Views 362

Implications of Wegovy's Medicare Price Negotiation The recent announcement regarding Medicare's negotiations for prescription medications has sparked considerable interest, particularly with the inclusion of Novo Nordisk's (NYSE: NVO) groundbreaking weight-loss drug, Wegovy. This decision marks a significant moment for both healthcare providers and patients across the...

Continue Reading
Max Stock Ltd. Receives Resignation News from Deputy CEO

Updated Category News Views 289

Max Stock Ltd. Announces Resignation of Deputy CEO Max Stock Limited (TASE: MAXO) has revealed that Mr. Nir Dagan, the Company’s Deputy CEO and Head of Finance, has decided to resign after nine impactful years of service. Mr. Dagan will remain in his position until the end of the calendar year. The Company appreciates Mr. Dagan’s extensive contribution over the years,...

Continue Reading